, Tracking Stock Market Picks
Enter Symbol:
BioSpecifics Technologies Corp (BSTC) [hlAlert]

up 218.00 %

BioSpecifics Technologies Corp (BSTC) rated Buy with price target $46 by MKM Partners

Posted on: Tuesday,  Nov 11, 2014  11:25 AM ET by MKM Partners

MKM Partners rated Buy BioSpecifics Technologies Corp (NASDAQ: BSTC) on 11/11/2014. Previously MKM Partners rated Buy BioSpecifics Technologies Corp (NASDAQ: BSTC) on
04/05/2012., when the stock price was $15.72. Since then, BioSpecifics Technologies Corp has gained 218.00% as of 09/28/2015's recent price of $49.99.
If you would have followed the previous MKM Partners's recommendation on BSTC, you would have gained 218% of your investment in 1271 days.

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. The indications are for the treatment of Dupuytren?s disease, Peyronie?s disease and frozen shoulder. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for injectable collagenase (which Auxilium has named XIAFLEX TM) for clinical indications in Dupuytren?s disease, Peyronie?s disease and frozen shoulder (adhesive capsulitis), and Auxilium has an option to acquire additional indications that it may pursue, including cellulite and lipomas.

MKM Partners LLC is an institutional equity trading and research firm. MKM Partners has extensive experience in the agency execution of U.S. and international equity orders. We provide clients with timely and unbiased economic, technical, and fundamental research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/11/2014 11:25 AM Buy
40.39 46.00
as of 10/17/2014
1 Week up  1.86 %
1 Month up  4.39 %
3 Months up  38.01 %
1 YTD up  61.00 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/9/2014 11:25 AM Buy
22.36 28.00
12/9/2013 11:25 AM Buy
23.39 24.50
4/5/2012 11:25 AM Buy
15.72 26.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy